Independent evergreen VC investing in early-stage Swedish deep tech and life science companies. Reinvests 100% of profits. Long-term, patient capital model.
Focus and check size from the firm's website. Website reachable as of Oct 2026.
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.